(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

Patients with A-fib and only one of the three dose-reduction criteria used in the ARISTOTLE trial—age 80 years or older, body weight 60 kg or less, and creatinine level 1.5 mg/dL or higher—have higher ...

ELIQUIS Dosage and Administration The recommended dose of ELIQUIS for most patients is 5 mg taken orally twice daily. In patients with any two of the following characteristics (age ≥80 years, body ...

DURHAM, NC — A secondary analysis of the ARISTOTLE trial supports using the standard 5-mg twice-daily dose of apixaban (Eliquis, Bristol-Myers Squibb) in patients with atrial fibrillation (AF) who ...

In subgroup analyses, the standard apixaban dose (5 mg twice daily) was significantly associated with a higher rate of the primary outcome and a higher incidence of fatal or intracranial bleeding and ...

heart ecg arrhythmia For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

UPDATE: With Multimedia: U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk ...

Please provide your email address to receive an email when new articles are posted on . Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous ...

Extended apixaban or dabigatran reduces recurrent VTE Extended anticoagulation with apixaban or dabigatran reduces recurrent VTE and mortality without increasing major bleeding. Level 1: Likely ...